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ABSTRACT
Introduction: The pharmaceutical industry is undergoing major shifts due to changing macro and
micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on
generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses
two completed deals in 2016 above 1bn USD. Thereafter one outlines the main motives behind M&A
deals and concluded by discussing whether M&A harms medical innovations.
Areas covered: The paper is based on empirical study questioning existing literature in order to
critically analyse valuation and the strategical orientation of pharmaceutical companies
Expert commentary: Pharmaceutical companies understand the changing market conditions and
favour their expertise. The restructuring of the industry moves to small niche companies (I.e.
Biopharma or biotech companies) researching key innovations and big companies purchasing them
to develop them, create clinical trials and distribute them as this is a costly manner
Conclusion: One can expect more M&A deals during the next years focusing on value rather than
volume. Pharmaceutical players resilient to the market changes may survive if they change their
business model from a traditional vertical one to outsourcing and diversification including external
players.
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The pharmaceutical industry is very capital intensive with
many barriers to entry such as high cost of research and
development (R&D) [pharmaceutical expenditure in R&D in
USA, Japan, and Europe is increasing massively each year,
1995: 29.8mn EUR, 2005: 63.14mn EUR (+112% from 1995 to
2005), 2015: 95.2mn EUR (+51% from 2005 to 2015 and +219%
from 1995 to 2015 [1])], regulatory policies, or pricing pres-
sures [2]. To remain profitable, companies need to build up
and enhance their economies of scale. A practice well known
in the industry is diversification by entering generic drug
research and manufacturing. This requires less capital but
comes also with lower profit margins. Patents are crucial for
pharmaceutical companies. The impact of expiring patents on
revenues is expected to reach 259bn USD between 2014 and
2020, with 70bn USD at risk in 2016/17. This involves all major
players, i.e. Pfizer’s Alimta against cancer expired 2016,
AstraZeneca’s Crestor for lowering LDL cholesterol expired
2016, or Merck’s Cubicin against bacterial infections also
expired in 2016, to name only a few [3]. Future estimates are
even more frightening with provision of sales at risk during
2017 and 2022 of USD 194bn due to expiring patents. This is
mainly linked to further growing external and internal factors
hitting pharmaceutical companies. Next to generics, pharma-
ceutical companies are also intensively looking at researching
and developing medicines for new drugs with rare diseases,
where they can demand reimbursed prices (i.e. cancer, orphan
diseases) or ask funding from governments for drugs such as
antibiotics to develop the market and enable sustainable
investments necessary for the development of highly scienti-
fically challenges discoveries or to collaborate with govern-
ments to help lower income countries to afford drugs (i.e.
Novartis trying to make cardiovascular diseases, diabetes,
respiratory diseases, and breast cancer affordable in Kenya
[4]). Both, strategy for generics diversification as well as colla-
borations developing are practices well known in the pharma-
ceutical industry.
This shows that major market players are seeking for alter-
native strategies to remain competitive and respond to the
increasing worldwide drug prescriptions that are expected to
grow at +6.5% compound annual growth rate until 2022 to
reach 1.06trn USD [5]. The 1.06trn USD target is split between
112bn USD generic sales (10.6%), 209bn USD orphan drug
sales (19.7%), and 739bn USD other sales of prescriptions
(69.7%) [5]. To respond to the fast-moving market, the new
demand from epidemiologic transition and to create new
innovative drugs, pharmaceutical companies are more strate-
gically looking for the generation of inorganic growth as
organic growth is moving at slow pace due to the hitting
external macro requirements. Inorganic growth is the growth
rate by growing profits through external deals such as colla-
borations, venture capitals, or Mergers and Acquisitions (M&A).
As pharmaceutical companies are strongly looking at M&A as
it allows growing the company earnings rapidly while creating
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meaningful synergies, this paper focuses solely on this growth
strategy.
The years 2014 and 2015 were strong years of M&A activity,
both in terms of volume and value. While 2016 saw some
signs of fatigue in terms of value with 325.8bn USD (vs.
451.5bn in 2014 and 578bn USD in 2015) [6], one can analyze
from Figure 1 that the 2016 figure is in line with the value in
prior years before the storm of 2014/15. The decrease in M&A
deals in 2016 was mainly driven by three factors: (1) the
Obama regime blocked transactions motivated by tax inver-
sions, (2) only few remaining targets after the big merger
mania in 2014/15, and (3) falling price/earnings (P/E) ratios at
lower end of historical levels with a stronger US dollar and a
slow adoption growth rates for some products [7].
Analysts are pretty optimistic for the upcoming years as
pharmaceutical companies feel the need to restructure their
portfolios with M&A representing the most efficient
instrument.
2. Methodology
This paper critically analyzes and investigates both valuation
and strategical orientation of M&A in the pharmaceutical indus-
try. For this research, one has gathered data through literature
reviews mainly researching for the big four accounting firms
(Deloitte, PwC, EY, KPMG), market observations and analyses
from financial specialists (consultants, investment bankers), top
newspapers (Reuters, CNBC), and the employment of the finan-
cial tool Bloomberg for market news, data, analysis to enable
one to make calculations. Literature was gathered by using the
main keywords: M&A, development, pharmaceutical industry,
restructuring, business model, valuation of companies, tender
offers, share prices, drugs, and portfolio.
This empirical research is introduced with a brief historical
development of M&A in the pharmaceutical industry to under-
stand the evolution of M&A transactions in terms of value and
volume over a 10-year horizon (2006–2016) (Figure 1) and
shows all M&A deals above 1bn USD completed in 2016 in
the pharmaceutical industry (Table 1).
Thereafter, one will outline the principles of valuation
including the most important calculation methods as it is a
complex discipline and needs to follow some main rules of
thumb to understand how much a company is worth.
Explaining the structure of a tender offer concludes the the-
ory, as the paper is focusing on two hostile takeovers.
After the fundamental theory and literature review has
been reviewed and explained, the researchers are analyzing
two examples of completed M&A deals above 1bn USD in
2016. Pfizer acquiring Medivation and Mylan acquiring Meda
to present the sequence within a tender offer and subse-
quently analyze the evolution of share prices from the acquirer
and the target through a scientific financial approach using
financial data providers. These two examples were chosen as
the median of M&A volumes above 1bn USD in 2016 is 8.32bn
USD, and these two examples are slightly above this median
and are in the top three completed deals. This allows going
beyond simple reporting observations and getting raw com-
plex data able to calculate and analyze, to show short and
long-term impacts of M&A transactions. This real-world envir-
onment allows to prove relevancy of valuation multiples.
In a second step, the research design focuses on the main
motives for M&A transactions and whether they are resilient to
the core business models of the acquirer. This part is based on
a fundamental literature review, manly using economical and
financial concepts, such as selling-off or Markowitz portfolio
theory, as well as a review of the US tax environment, to
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Figure 1. Evolution of M&A Deals in the Pharmaceutical Industry over a 10-year time horizon.
Source: KPMG Predictor [6]












Horizon Pharma Raptor Pharmaceutical 1.5bn
Galencia Relypsa 1.4bn
Jazz Pharmaceuticals Celator Pharmaceuticals 1.2bn
This means that there were various small deals next to the nine big deals in
2016 for 250.9bn USD (the total M&A value in 2016 was of 325.8bn USD).
























In a third step, the empirical research undergoes a brief
discussion whether M&A harms innovations in the pharma-
ceutical industry and then concludes with a recommendation
plan for pharmaceutical companies.
3. Valuation of a pharmaceutical company
3.1. What is valuation?
Valuation is the procedure of defining the current worth of
an asset. Analysts are using different factors, techniques,
and calculation methods to define the right value. Main
factors they are looking at are the management of the
company, the capital structure (financing of the company
operations and potential growth opportunities, meaning
equity or debt), the future earnings, and the market
value (i.e. what the company is worth in the market, or
what the underlying assets are worth in the market) [9].
This means that valuation depends on not only various
internal factors, such as the drug pipeline, patent rights,
M&A activities, the overall company health, but also the
market potentials and some external macro trends. Also,
the market value is defined by what an acquirer is willing
to pay to its target. When companies are traded on a stock
exchange, the target is defined by the market value of the
stock.
3.2. How to value a company?
In order to value a company, analysts are using different
approaches. The three main approaches to consider are the
asset, the market, and the income approach. One explains all
three approaches below, focusing on the income approach as
it allows to define the overall economic value of a business.
3.2.1. Asset approach
One valuation method is the asset accumulation. It measures
the difference between the current value of all underlying
assets in one business and the current value of all the com-
pany’s liabilities (loans, accounts payable, deferred revenues,
and accrued expenses). It allows showing the fair market
value, so the fair value that a buyer would offer to its target.
Interesting about the asset accumulation is that off-balance
sheet variables are included in the valuation, such as IP, exclu-
sive contracts with distributors, any strategic contracts, or
partnership agreements. This approach shows the valuation
of the underlying assets in one company.
3.2.2. Market approach
The market approach is used to calculate the appraisal value
of an asset, meaning the valuation of a business or real estate
by an authorized person (i.e. auditor) based on the selling
price of a similar asset. It shows the value of a company’s
ownership interest, security, and tangible assets. All assets are
valued against recent sales of similar assets, by making adjust-
ments for size, quantity, and quality.
3.2.3. Income approach
This valuation looks at the economic value of a business by
analyzing future returns the acquirer can expect from the
target. To do so, one calculates various multiples that will be
discussed in a next step:
The impact of earnings on valuations and the overall com-
pany valuation are key considerations:
(1) Earnings on valuations: Earnings per share (EPS): When
analysts are using the EPS formula, they divide the
earnings available to the existing shareholders by the
number of outstanding stock shares. EPS is calculated
to understand how profitable a company is. The more
earnings a firm generates per share, the more attractive
and valuable every share is to the investors. In 2016,
one has downgrading earning momentums, especially
with US large caps as concerns on US drugs pricing are
present due to major abuses (i.e. EpiPen, Section 2.2).
(2) Earnings on valuations: P/E ratio: Also, analysts are
using the P/E ratio to value a stock, calculated by
dividing the market price per share by the EPS. This
ratio expresses how expensive a price of a stock is
compared to the earnings created per share. Also, this
translates into how much an investor is willing to pay
for each dollar of earnings. Once an analyst has calcu-
lated the P/E ratio, and the stock would show for
instance 30 times earnings, the analyst would compare
it to the benchmark ratio and/or competitors from the
same industry ratio to see the attractiveness of the firm.
For instance, Novartis shows very strong P/E at 28.8×
compared to 20.76× of the free-float weighted equity
index MSCI World Index, including mid and large-cap
performance across 23 developed market countries (30
December 2016). However, overall pharmaceutical
stock valuation is also at the lower end of historical
levels trading with US large cap trading average at
15× and European large cap average at 14× [10].
(3) Overall company valuation: However, some analysts
prefer the Enterprise Value to Earnings Before Interest,
Depreciation, Taxes, and Amortization (EV/EBITDA) ratio
as opposite to the two abovementioned earnings on
valuations multiples (EPS, P/E). This ratio is expressed
for very capital intensive companies and the valuation
preference is due to it shows the overall company value
and is capital structure neutral. Also, it is more precise
than the P/E ratio, as it includes the operational earn-
ings (EBITDA vs. the net profit) and the overall company
value (including debt, cash, and minority interests). The
EV/EBITDA shows whether a company is over- or under-
valued. For instance, in 2015, Europe showed to be a
seller market, with an average valuation of 17× EBITDA
[11].
One believes that the calculation of all three multiples is the best
to use when valuing bigger pharmaceutical companies due to
their relatively stable earnings and capital intensive businesses.
Thereunto, analysts are putting a value to the asset by calcu-
lating the cash inflow and outflows created by this asset. One
























discounts the cash flows (CFs) in a value by using the discount
rate. The discount rate expresses an assumption of interest rates
or the minimal return rate what an investor would expect. For
instance, when a company is purchasing a new drug, the com-
panywill analyze on one side the cash outflows necessary for this
purchase and on the other side, it will calculate the cash inflows
generated by this new drug. The CFs are discounted to the
present value. If this present value also called net present value
shows a positive number, the company should consider the
purchase as the investment is a good buy. Therefore, the CF
shows the movement of cash inflow (revenues) and outflows
(expenditures) created from an asset or firm. This means that
the CF determines the liquidity of a firm.
On the other side, the free cash flow (FCF) is calculated as
difference between the operating CF and the actual capital
expenditure (equipment, buildings, etc.). This FCF shows the
actual cash available to the company and expresses therefore
the financial performance of a company. If cash is available, it
creates new opportunities that augment the shareholder value,
as for instance dividends would be higher if more cash is avail-
able, or new assets could be founded that could increase the
share price. It shows howmuch cash can be apportioned among
all the shareholders. This means that the FCF determines the
overall financial health of a company. A positive FCF expresses
that the company has enough cash to run its business efficiently,
while a negative FCF shows that the company is not able to
create enough cash or has overinvested somemoney that might
create higher returns in future periods.
Table 2 shows a summary of CF and FCF as all investment
and financing choices are conditioned by these two aspects.
Table 3 shows a summary of what the three approaches
express for a company.
3.3. Valuation of deals above USD 1bn in 2016
The pharmaceutical industry is an industry spending a lot of
capital on their R&D activity. It takes an average of 12 years that
a new drug is researched and brought to the patient. In addition,
only 5 out of 5000 are actually passing the preclinical testing to the
human testing. Finally, only one out of five is approved for human
use [13]. This shows that pharmaceutical companies need to be
very stable to create profitability and organic growth. As high-
lighted, this is very difficult nowadays and therefore companies
are looking for external growth. In order to achieve external
growth, pharmaceutical companies need to target the right com-
pany, reason why the financial metrics described here above are
calculated and analyzed to show the potential return on invest-
ment a company and its investors would achieve.
As the top pharmaceutical companies are publicly traded,
the financial data are available to the market and one can
compare the companies and their assets with competitors and
industry multiples. Table 4 is comparing the key multiples of
the acquirer and target companies involved in the 2016 deals
above USD 1bn.
Comparing the key financial multiples of the pharmaceuti-
cal companies involved in 2016 deals above 1bn USD in
Table 4 to the benchmark MSCI World Index, one can analyze
the following:
● The average EV/EBITDA is at 14.59× versus 12.05× of the
benchmark, with all acquirer companies above the
benchmark.
● The average P/E ratio is at 17.37× versus 21.05× of the
benchmark, with all acquirer companies below the
benchmark.
● The average P/CF ratio is at 12.66× versus 11.43× of the
benchmark, with Mylan and Horizon Pharma below
average.
Concluding, the acquirer has a target company to take over, and
the dedicated Investment Bankers calculate all multiples and
factors described here above. This allows the acquirer to justify
the valuation of the target and vice-versa including the takeover
price estimation, with the premium included. The intention of the
acquirer is to minimize the amount that needs to be paid to the
target shareholders, while the target’s aim is to maximize the
amount that will be paid to its shareholders. This means that in
an ideal world, the acquirer does not want to pay more than the
premerger value of the target plus the value of the synergies, but
the target shareholders want to maximize their gains and would
not accept anything below the premerger market value. The
formula to apply to calculate the target shareholder’s gain would
be as follows: Premium = PT − VT, where PT equals the price to pay
for the target company and VT expressing the premerger value of
the target company. This means that the acquirer gain equals the
synergies minus the premium or with the formula: Acquirer
gain = S − (PT − VT), with S presenting the synergies created by
the combination of the two businesses. Summing up, the com-
bined formula to calculate would be as follows:
Post-merger value of the combined
companies = VA + VT + S − C, where VA is the premerger
value of the acquirer and C is the actual cash paid to the target
shareholders.
In a further step, one will explain the valuation of two big
pharmaceutical companies that were involved in M&A deals
above USD 1bn in 2016, Pfizer acquiring Medivation and Mylan
merging with Meda. Both companies have used tender offers
to complete the transactions. Tender offers are widely used in
the M&A business, as hostile takeover, where the offer is
directly made to the target’s shareholders, not to the target
Table 2. Resume of CF and FCF [12].
Cash flow Free cash flow
Definition Cash inflows and cash
outflows
Available cash to a company (that can be
paid out to shareholders or invested)
Reason Solvency of the firm Performance of the firm
Calculation Sum of all revenues –
sum of all
expenditures
EBITDA – working capital
changes + capital expenditure
Result Liquidity of the
company
Overall financial health of the
company
Table 3. Summary of the tree main value approaches.
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board. Figure 2 illustrates the structure of a tender offer which
has two major steps.
In a two-step merger, the target will become a wholly
owned subsidiary of the acquirer. The acquirer starts a tender
for all the target’s shares and can be completed in a few days.
In case that the transaction is fully cashed, the merger can be
completed in 1–2 months in case no regulatory issues occur.
Once the target shareholders have agreed to the tender, the
acquirer purchases all tendered shares and becomes a major-
ity shareholder of the target to follow up with a merger. The
target continues to exist, but the acquirer gains full control.
3.3.1. The tender offer of Pfizer acquiring Medivation for
USD 14bn
Pfizer, one of the world’s largest pharmaceutical companies
based in the Unites States, offers drugs for immunology,
oncology, cardiology, and neurology. Its size allows them to
have competitive advantage in developing new drugs, hold-
ing a portfolio of patent-protected medicine with strong pri-
cing power, allowing the company to generate low volatility
CFs and return on invested capital in excess of its cost of
capital. However, as patents are expiring, the company loses
exclusivity on drugs, for instance on their drug against cho-
lesterol Lipitor or the blockbusters Celebrex or Zyvox.
Therefore, the company aims to create fast external growth
rather than slow organic growth through its M&A activity.
After Pfizer’s default in 2016 buying Allergan to save almost
125mn USD of taxes, they made a tender offer to Medivation,
the cancer drug developer, in order to keep its leading posi-
tion in oncology [15].
Pfizer made a tender offer for all outstanding shares of
Medivation with transaction value of USD 81.50 per share in
cash, for a total enterprise value of USD 14bn. In total
115,574,041 shares were tendered, translated into a 69.1%
acceptance rate of existing shareholders, excluding any
interest. This share price represents a 21% premium compared
to Medivation’s share price on Friday, 18 August 2016 at USD
67.19, and above the record close of Medivation in March 2015
of 67.78 USD per share. The transaction was paid by Pfizer with
existing cash. All shares that were not tendered were acquired
in a second step in 2016. Medivation was in focus as target of
many big pharma companies, due to its unique position in the
biopharmaceutical sector focusing on innovative therapies
treating serious diseases where today’s treatments are very
limited such as in prostate cancer [16]. Sanofi also tried to
target Medivation, however with a very aggressive takeover
offer of USD 9.3bn, that was rejected.
Pfizer’s Board of Directors and Medivation have both agreed
to the merger, being immediately accretive to Pfizer’s adjusted
diluted EPS upon closing. The diluted EPS is a profitability
measure taking into account all convertible securities which
express the quality of EPS of a company, with the assumption
that all convertible securities (including all outstanding con-
vertible preferred shares, convertible debt, equity options,
employee-based options, warrants) are exercised. Pfizer’s
adjusted EPS was of USD 0.05 accretive in the first full year
after deal close with additional accretion potential and growth
anticipation. Medivation’s shares have risen by 66% from
January to August 2016 [17]. Pfizer’s shares have dropped 1%
on Monday, 22 August 2016 when the acquirer announced to
buy Medivation. This significant short-term change in share
price is normality with M&A transactions. The share prices of
the acquirer normally drop as the acquirer needs to pay more
than the target company is currently worth to create an
attractive offer. Thereunto uncertainties around M&A deals
drop the acquirer share price, such as additional debt or
expenses that will be taken over by the acquirer to make the
deal go through or accounting issues such as restructuring
charges. However, one can analyze that if a transaction goes
efficiently, the drop is of short-term nature and the acquisition
Step 1:
1. A, T and MS sign 3. Board T recommends TS
merger agreement to tender to MS
4. TS tender
2. MS makes offer 5. MS accepts and pays for




Acquirer (A) +50% of target shareholders (TS)




Figure 2. Two-Step Tender Offer Structure.
























is normally a good deal for the acquirer in the long-term run if
the right company has been chosen and valued adequately,
and previously financial economic considerations have been
thought of.
Figure 3 analyzes in more detail the share price movements
of Pfizer and Medivation since beginning of 2016, where
Medivation become very attractive to big pharmaceutical com-
panies (Pfizer, Sanofi etc.) until Pfizer’s takeover.
In February 2016, the US FDA approved some additional
new drug applications for Medivations core drug Xtandi that
allows including TERRAIN and STRIVE trials. The TERRAIN trial
compares enzalutamide versus biculutamide in men who do
not have symptoms with metastatic diseases progressing on
hormone therapy. The STRIVE trials compare castration-resis-
tant non-metastatic or metastatic diseases [18]. Thereunto,
Medivation made a presentation at the American Association
for Cancer Research on 17 April 2016 announcing phase I of
Talazoparib. Both events were positively received, with conse-
quently jumping share prices. Adding to these two research
events, the biopharmaceutical company received on 15th
April a nonbinding offer from Sanofi to acquire all outstanding
shares at a price of USD 52.50 per share, representing an
undervaluation of the company. However, speculations on a
takeover started already beginning of the year that caused a
surge in Medivation’s share price.
In Q3 2016, Pfizer made the offer to Medivation at a fair
value of USD 81.50 per share reprinting a premium of 21%
compared to the share price of 67.19 on 18th August. On 22nd
August when the deal was officially announced, the share
price climbed to USD 80.42, closing at USD 81.44 on the deal
closing day 27th September.
Pfizer shows that it is a well-perceived pharmaceutical
company with less volatile share prices. On 18th August, its
share price was of USD 35.19 per share falling slightly of 99bps
to USD 34.84 on 22nd August. Until deal closed, it lost addi-
tional 2.90%, totaling a short-term loss of 3.86% in the acquisi-
tion period of Medivation. Since the deal closed until 18
August 2017, Pfizer’s share prices increased for +2.51, with
return figures for the year of 2016 of +4.46%. It shows that
in a long-term run, the acquisition did not hit the stock price
and translated into a good acquisition and positive share price
results.
The aim of this transaction for Pfizer is to grow revenues,
drive earnings growth, and become a leader in oncology.
Pfizer’s group president A. Bourla analyzes the transaction:
Given the breadth of Pfizer’s existing oncology portfolio and emer-
ging immuno-oncology pipeline, Medivation’s assets will poten-
tially benefit from many novel and productive combinations.
Together, we are well positioned to becoming a leading oncology
company, speeding cures and making accessible breakthrough
medicines to patients – our number one priority. [19]
The target became a wholly owned subsidiary of the acquirer.
The two companies started their joint operations on 28
September 2016 to increase their market power and commer-
cial scale in oncology focusing on new cancer treatment inno-
vations. This tender offer shows how capital can be deployed
in an effective way to generate attractive returns and create
additional shareholder value. Pfizer acquired the key innova-
tive prostate cancer drug Xtdandi, blocking various steps in
the androgen receptor pathway in the cell affected by the
tumor. Xtdandi has achieved USD 2.2bn net sales in 1 year.
Moreover, the late-stage oncology pipeline of Medivation is
very attractive and adds value to Pfizer’s portfolio, such as
Talazoparib which is in Phase III study treating breast cancer
or Pidilizumab developed to diffuse B-cell lymphoma.
This acquisition allows Pfizer to strengthen its position in
the field of oncology, important as cancer remains the second
leading cause of death worldwide [20].
Figure 3. Evolution of Medivation’s share price versus Pfizer’s share price. The white line shows Pfizer’s share price evolution and the red line shows Medivation’s
share price movement [10]. Full color available online.
























3.3.2. Second example of Mylan acquiring Meda in a
tender offer for USD 9.9bn
Mylan, the global pharmaceutical company from the United
States, made a tender offer to Meda, a Swedish drug maker on
16 February 2016 for all their shares. The entire offer consists
of cash and Mylan ordinary shares with a value of SEK 165
(USD 20.22) per Meda share. The total value for the transaction
is of USD 9.9bn (USD 7.2bn without debt) showing a multiple
of 8.9× EBITDA including synergies (12.9× EBITDA without
synergies). Prior to the announcement, Meda’s valuation was
at 3.7bn USD [21]. Meda’s board of directors recommended to
its shareholder to accept this offer due to its significant pre-
mium delivering immediate shareholder value. Also, Meda’s
two largest stakeholders holding approximately 30% of out-
standing shares accepted the offer, in contrast to its rejection
in 2014 where Mylan wanted to acquire Meda for USD
6.7bn [22].
After the announcement, Mylan’s share price dropped by
18% due to several reasons. First, the earnings in Q4 2016
were negatively impacted by higher nonoperating expenses
(i.e. unrealized mark-to-market losses on Mylan’s Swedish cur-
rency contracts) that distressed the investors. Second, Mylan’s
investors disliked the noise to acquire Meda, as they did
already a first offer in 2014 that was rejected. Third, Mylan
paid a very high premium of 92% over Meda’s market value,
which defines one of the highest premiums ever made in the
pharmaceutical industry [23]. Moreover, this deal was made
after the merger-mania 2015 in a year where companies were
overvalued. Lastly, it has to be said that Mylan not only made
different M&A attempts such as the hostile failed attempt to
acquire the drug maker Perrigo but also made some deals that
made derogatory headlines such as the deal with Abbott INC’s
specialty and generic business, based in the Netherlands, only
for tax inversions.
With the acquisition of Meda, Mylan can benefit from a
similar portfolio to Perrigo, with over-the-counter (OTC)
drugs. However, one can mention that Mylan’s success is
based on M&A deals, as it was a much smaller company
10 years ago. The deal of Mylan acquiring Meda was com-
pleted on 5 August 2016 strengthening its global diversified
portfolio and gain market access in China, South Asia, Russia,
and the Middle East. This allows Mylan to become a leading
global player in the field of allergies and respiratory and add
significant value in dermatology and pain treatments.
This deal should be immediately accretive adding USD
0.35–0.40 to the diluted EPS. Moreover, operational synergies
are expected to be of USD 350mn annually.
Figure 4 shows the evolution of Meda’s versus Mylan’s share
price since announcement of the deal. On 9 February 2016,
Meda’s share price was at SEK 83.05 (USD 10.22), climbing in
2 days to SEK 143.90 (USD 17.71) presenting a 73.27%
increase. In the week when the offer was finalized, the price
increased further 11.67% to SEK 160.70 (USD 19.78) presenting
Meda’s high during its lifetime, seeing SEK 154 (USD 18.95) on
the day of the deal closing (05 August 2016) and closing off on
23rd August at SEK 156 (19.20 USD). This means that since
announcement to close Meda’s share price rose in total by
87.84%.
On the other side, the share prices of Mylan dropped from
9th February to 11th February by 18.37% from USD 50.74 to
41.42 USD. Until the last week of the deal close, Mylan’s share
increased back 17% to USD 48.46 on deal closing day. This
shows that the acquisition of Meda was relatively neutral for
Mylan with only short-term lows in the share price.
These two examples of Pfizer acquiring Medivation and
Mylan acquiring Meda show that on a short-term basis the
valuation of the acquirer (incl. share prices) decline due to
various reasons such as high volatility in share prices, the
Figure 4. Evolution of Meda’s versus Mylan’s share price. The white line shows Mylan’s share price evolution and the red line shows Meda’s share price movement
[24]. Full color available online.
























acquirer taking on too much debt, lack of synergies or too
high premiums paid to the target, but in the absence of
unknown economic conditions recover rapidly shifting
towards a higher valuation of the acquirer and target
together, due to the share price arbitrage. Share price arbit-
rage means taking on a long position in shares of the target
and a simultaneous short position in the acquirer shares, once
the takeover is public. Also, long-term performance increases
in the absence of economic uncertainties and greater divi-
dends might be paid to shareholders.
4. Are the transactions strategically oriented,
resilient to the core business model?
With a second research question, this paper aims to analyze
first the main motives behind M&A deals, an ex-ante concept,
and second whether M&A transactions in the pharmaceutical
industry are strategically oriented, resilient to the core busi-
ness model, an ex-post concept. As markets remain volatile,
competition increases and internal R&D is often cost and time
efficient, big players are looking for external alternatives, with
M&A as valuable strategy, to answer the increasing demand
(i.e. epidemiologic transition) and comply with new regula-
tions and pricing pressures.
Analyzing the M&A deals achieved between 2006 and 2016,
one has identified three main motives for M&A transactions:
(1) Restructuring of the entire business operations or part
of it to gain more purchasing capacities and selling of
noncore assets to improve profitability and add value
on niche parts of the business
(2) Enhancing the portfolio through the acquisition of new
drugs to remain a competitive market player and grow
inorganically
(3) Shifting of the tax domicile through tax inversion deals
In a next step, one will outline the three motives described
here above through real examples including the resilience to
the core business strategy.
4.1. Restructuring and selling of noncore assets
Companies are using M&A activities to sell noncore assets of
the company, in order to focus on key assets. For instance, the
British pharmaceutical company AstraZeneca has decided to
sell off different noncore assets within the company. To name
some examples of AstraZeneca to reduce their portfolio diver-
sity and sell of noncore assets, are for instance the Alzheimer
drug that was sold to Eli Lily for more than USD 500mn, or
another USD 200mn deal with Daiichi Sankyo, or a USD 300mn
deal with Recordati for its aging beta-blocker heart drug
Seloken [25]. The idea behind selling-off noncore parts of the
business is to spin-off costly areas that don’t drive revenues
upward, and to focus on key resources and target new assets
that are more in line with the key business strategy and can
deliver growth. This strategy allows funding new assets by
existing funds, rather than growing one’s debt. Also, spin-
offs are implemented to help stabilizing earnings when
patents are expiring. Moreover, it allows saving costs on
noncore assets through the reduction of cost or production,
financial, or fixed costs [26].
Another supporter of this rationalization concept is the
Swiss pharmaceutical company Novartis, selling off noncore
assets to add cash and focus sales on key assets. Novartis has
for instance sold some different products to the Indian phar-
maceutical company Sun in Japan for USD 293mn, as they had
own issues entering the Japanese market [27].
Noncore assets are neither essential nor used by the busi-
ness to generate core revenues. However, they help to deploy
cash for future assets that might have massive growth char-
acters. For instance, AstraZeneca sold off their noncore assets
to invest into the development of new drugs that could be
blockbusters in the area of oncology and other severe dis-
eases. GlaxoSmithKline also used this practice to offload differ-
ent noncore assets. Selling-off noncore business parts is often
used as short-term or medium-term strategy to reduce the
level of debt or have enough capacities to manoeuver for new
long-term acquisitions [28].
This shows that selling-off noncore parts of a business is a
strategic decision of pharmaceutical companies, resilient to
the core business model to focus on the growth generating
assets and generate CFs for future acquisitions of core assets.
4.2. Grow bigger by building a sustainable portfolio and
valuation
Next to selling-off noncore assets, M&A deals are favored in
the pharmaceutical sector to enhance one’s portfolio, diversify
globally, and keep their revenues growing in the expected
investors pace. As presented, it gets more difficult for pharma-
ceutical companies to breakthrough with new innovative
drugs, as costs are increasing, regulations are tightened, and
demand more sophisticated. Therefore, it is often cheaper to
acquire an existing drug or even an entire company with an
existing asset portfolio rather than developing in house ab
initio. This motivation is enhanced through low interest rates
that translate into cheap capital, easy to fund the acquisitions
with debt. Diversification in different areas related to the
modern portfolio theory [28], which explains that the market
value of a company can increase when one invests into differ-
ent assets, especially if they are less correlated, however differ-
ing from conglomerate mergers, mergers that are transactions
between firms of totally unrelated business activities [29]. As
outlined in the modern portfolio theory, mergers area also a
way to diversify risk and maximize expected returns [30].
Such an event was seen in the previously analyzed Mylan
acquiring Meda case. Mylan’s reasons behind the Meda bid
was to enhance the portfolio of generic drugs and OTC med-
icines, entering into emerging markets (i.e. China, Russia, or
the Middle East) and therefore become a leading global firm
that competes with Teva, Pfizer, and Perrigo. Mylan expects to
generate savings around 350mn USD by leveraging operations
between both companies. This allows to move from a pure
generic prescription drug maker to a diversified health-care
company available on a global level.
Mylan sales grew significantly higher from 2.6bn in Q2 2016
to 3.3bn in Q4 2016, toward 2.7bn USD in Q1 2017, represent-
ing a year-on-year growth of 24.1%. The net profit was higher
























than the industry average hiking to 12.8% in Q4 2016 stabiliz-
ing at 2.4% in Q1 2017. Mylan’s operating CF is healthy at
425.6mn USD and net income of 66.4mn USD. The company
shows a high return on equity (ROE) at 4.8% and a good FCF
margin at 15.6%.
The earnings multiple is appealing. Mylan showing a P/E
ratio of 38.8, compared to the benchmark S&P 500 at 21.4. The
price/sales multiple shows the current stock price to the total
assets, showing Mylan at 1.8 in favor to the S&P 500 at 2.1. This
shows that the stock is attractive, however currently overva-
lued. Under- and overvaluation of the stock depends on
macro-factors and market conditions. EPS, showing the profit-
ability of one single share, shows healthy data at 0.93. Finally,
the market capitalization, representing the price to buy a firm,
is performing positively at 20.51bn, suggesting that Mylan
shares are safer than lower market capitalization firms.
Pursuing a deal by acquiring a target boosts the acquirer
revenue growth, translating into a growth of share price.
Overall, one can say that the acquisition of Meda was
positive for Mylan to externally grow with global competitive
market advantages. The firm shows solid operating margins,
good net margins, healthy FCF margins, and high ROE.
Negative aspect of the transaction was that Mylan bought
also Meda’s debt, leaving Mylan with a high debt burden at
16.4bn USD, showing a debt/equity ratio of 1.41.
However due to their abuse in price hike for the epinephr-
ine auto injector EpiPen, they entered in Q2 2017 into a lawsuit
for the violation of consumer protection laws. Therefore, the
share price has dropped in April 2017 significantly. This trans-
lates, if an investor bought 100 shares of Mylan on the
announcement day to buy Meda (16 February 2016) at the
share price of 43.15 USD per share, Year-to-date (YTD) his
value (24 July 2017) would have dropped by 10.03% to 38.82
USD per share.
4.3. Tax inversion
Tax inversion formed also a major motive for M&A deals
during recent years as the corporate tax in the United States
is at 35%, the highest of all developed countries. One needs to
mention that the practice of tax inversion started already back
in the 1990s shifting primarily to Bermuda or Cayman islands
through the creation of a new holding (subsidiary) owned and
operated by the founding company that allows paying US
taxes on income earned in the offshore country. Therefore,
the US tax code Article 1248 taxing gains from certain sales or
exchanges of stock in certain foreign corporations [31] with
the goal to discourage tax inversions was created. Tax inver-
sion is a lucrative tax strategy for all corporations by relocating
a legal domicile to a lower tax nation (i.e. Ireland,
Netherlands), often by retaining the material operation in the
higher tax-country nation. In the pharmaceutical industry, this
phenomenon was majorly seen by buying smaller competitors
in a tax heaven and reincorporating in a foreign country. This
allows that the profits generated abroad are taxed domesti-
cally with the difference between the United States and the
rate of the foreign country. An example is Pfizer targeting
Allergan based in Ireland, in November 2015. By shifting
Pfizer’s tax domicile to Ireland, they would pay for every dollar
earned in profit 12.5 cents tax in Ireland (12.5% corporate tax
rate in Ireland) plus 22.5 cents in the United States, but the last
one only when the profits would be brought back to the
United States. This deal would have allowed Pfizer benefiting
from lower corporate tax rates as they are generating a huge
proportion of cash abroad. US companies are trying to gen-
erate profits overseas and invest them back in offshore opera-
tions to avoid the US taxes (i.e. 22.5 cents in Pfizer’s case) [32].
As the 152bn USD mega merger would have created one
of the biggest US tax inversions, the White House started
considering laws halting inversions or even prohibiting them
completely, as they could destroy the US tax base, i.e. mak-
ing earning stripping less attractive, by decreasing compa-
nies’ offshore profits shift abroad by applying intracompany
loans; or at least 25% of the group’s employees, assets, and
income have to be located or at least derived in the tax
heaven, in contrast to previously 10%; or US firms must
merge with bigger companies to avoid that US shareholders
have more than 80% by vote and value. Otherwise, the
offshore company would still be treated as US firm must
be paying taxes in income received in the United States and
repatriated income earned abroad. This shows that Obama
was strictly against these deals, as less tax revenues mean
for the country less money for infrastructure, schools, trans-
portation, and creating a bigger cliff between the social
classes. Obama mentioned, ‘When companies exploit loop-
holes like this it makes it harder to invest in the things that
are going to keep America’s economy going strong for
future generations’ [33]. Therefore, the attempt from
Chicago-based company AbbVie trying to buy the Irish phar-
maceutical company Shire for USD 52bn also collapsed as
AbbVie’s overseas cash that would have funded the deal
would have taxed by the US corporate tax [34].
Recent analysis from the Institute of Taxation and Economic
Policy (ITEP) showed that the Fortune 500 companies have
avoided over USD 767bn in federal US income taxes [35]. This
shows that tax inversions can still be strategically vice very lucra-
tive for growing bigger, increasing competitive advantage and
often answer shareholder expectations as they minimize the over-
all tax expenses, and therefore dividends might become higher.
However, the social and ethical factors can be controversial as tax
avoidance in the United States harm the government and there-
fore overall society [36]. This said in case that companies increase
the dividends, the logical consequence of tax growth is behind, as
shareholders have to pay taxes on their dividends.
According to the ITEP, the Fortune 500 companies are
holding USD 2.6trn non-repatriated money abroad, where
they often had to pay less than 10% income tax [37].
Repatriation of the money would foster the US economy
(i.e. acquisition of new machines, research places, new
employment, etc.), but it will only take place in case of
more advantageous US rates, as they are subject to US tax
rates of 35% minus the tax credit (tax paid to the foreign
government).
This shows that tax inversion can be a strategic decision,
also used by pharmaceutical companies, such as Mylan acquir-
ing Abbott’s specialty and generic business in non-US devel-
oped markets for 5.3bn USD to shift the tax domicile to the
Netherlands, allowing them to decrease their taxed to the
























high tenner [36]. One can argue that this practice is also
resilient to the core business strategy as pharmaceutical
players want to save costs and grow organically as much as
they can.
This said, the importance lies with the Trump’s Q3/Q4
reforms to harmonize the US corporate tax rate with other
competitive countries, lowering them closer to 20% [38]. On 2
December 2017, the Senate passed the tax plan lowering the
corporate tax rate from 35% to 20% and future foreign profits
of US-based firms would be mostly exempt from tax [39]. This
said, pharmaceutical companies would benefit from this
reduced tax rate, also on repatriated earnings, and therefore
would reduce focusing tax heavens outside the United States.
5. Are M&A deals in the pharmaceutical industry
harming medical innovation?
Lastly, this paper focuses briefly whether M&A deals in the
pharmaceutical industry harm medical innovation. The biggest
concerns of M&A deals for scientists and patients are that first
they concentrate the market, leading to fewer innovations and
second increasing the market share of few leading companies
mainly in terms of marketing, sales, and distributions and
therefore decrease competition.
(1) M&A is changing the market landscape; however, it
does not decrease innovations. Figure 5 shows that
even in the megamerger years 2014/15, filings were at
their record highs with 40, respectively, 41 filings, and
40 approvals in 2014 (11 biologics license approvals
and 30 new drug approvals) and 45 approvals in 2015
(12 biologics license approvals and 33 new drug
approvals). The year 2016 shows some signs of fatigue,
with only in total 19 new molecular entities FDA
approvals, but 36 filling received. This shows that
M&A activity is not a factor of fewer innovations, and
the industry is bringing new drugs to the market.
One can argue that the big companies are dependent on
acquiring smaller, niche-specialized firms (i.e. biopharmaceuti-
cal companies, tech firms), to fuel their pipeline and remain
competitive. The increase in M&A reflects this transformation.
(1) Second concern was that large companies increase
their market share, mainly in terms of marketing,
sales, and distributions and therefore decrease compe-
tition. New regulations, pricing pressures are increasing
costs that small companies cannot cover. Therefore,
small companies often opt to sell their niche innovation
assets or entire companies to bigger companies, and
big companies benefit as they can leverage their exist-
ing marketing and distribution channels. Another com-
petitive advantage of larger companies is that they can
cover the costs of filling with the FDA. This shows that
in a decade where blockbusters are expiring, M&A is a
significant driver trying to find new drugs, with small
companies being the innovators, and large companies
being the acquirer of innovations and adding value to
the commercialization of new drugs [41]. This shows
that M&A changes the industry but does not create any
harm, as small companies are creating innovation, and
large companies are taking over when it becomes too
costly for the small players.
This means that M&A transactions are structurally changing
the pharmaceutical industry, but it has been proven that
innovations are not harmed through mergers. M&A creates
vibration and it will depend manly on external factors, such
as regulatory requirements or pricing pressures.
6. Conclusion
One can say that the pharmaceutical industry is undergoing
major shifts in modern history. The industry has already
experienced major changes, and it is still in a state of
Figure 5. # of Drug Fillings and Approvals by FDA, 1996–2016 [40].
























continuous movements. On the one side of the coin, the
industry and its stakeholders are consistently challenged, as
patents are expiring, competition increasing, profits declining,
and costs exploding. On top of that, political and economic
movements are challenging the entire industry, such as the
Brexit or elections with Trump’s election in the United States
and also a turbulent election area in Europe. As outlined
above, the question is not if one can survive but rather how
companies can thrive.
However, on the good side of the coin, knowledge and
experience in health with high infrastructure, access to new
innovative drugs and therapies, an increase in global wealth
with less unemployment, more society knowledge through
self-education, and labor are the three key areas increasing
the pharmaceutical industry. Both sides of the coin are chal-
lenging the pharmaceutical industry, and therefore pharma-
ceutical companies need more than ever take control in
advance by anticipating changes through knowing the entire
macro- and micro-landscape.
The pharmaceutical industry will be dominated by pharma-
ceutical companies that are able to react to internal and
external changes and enhance their competences by taking
advantage of movements. This can be done as outlined in this
paper either by in-house innovations, however that is very
costly and time constraining, or by outsourcing through col-
laborations or M&A deals. The core focus is finding new inno-
vative molecules and therapies by focusing on specialist
pipelines that enhance and save human lives. Therefore, the
recommendation goes to the shark theory, meaning that big
pharmaceutical companies should benefit from their luxury of
the ability of making key decisions and acquire vital research
and early clinical trial stages from smaller competitors focus-
ing only on view niche molecules (i.e. biopharmaceutical or
biotech companies), to develop costly late stage clinical trials,
meeting all required regulations, and create the distributional
access to patients for the new drugs. In the next years, one
can expect that M&A deals are rebounding in terms of value as
(1) large players are looking to get rapid and efficient drugs in
their pipelines, meaning also an increase of filling with the
FDA and (2) the financial future seems overall healthy as debt
is cheap, companies have good CFs, and the big companies
have still strong P/E ratios.
7. Expert commentary
The pharmaceutical industry is undergoing major changes due
to a changing macro- and micro-landscape. On top of external
changes, patents are expiring which harms the revenues. To
respond the fast-moving environment, and to create new inno-
vative drugs, pharmaceutical companies are strategically look-
ing to generate inorganic growth through M&A, venture capitals
or partnerships. Main motives behind consolidations such as
M&A are selling off noncore assets, enhancing the existing
portfolio inorganically and diversify, as well as tax inversion in
regards to US companies. This said, one sees a consolidation and
shift of the entire pharmaceutical industry. Scientists and
patients fear that through an increase in M&A activity, innova-
tions will decline as the market gets less penetrated and motiva-
tion for innovation would shrink. However, looking at the last
years of M&A and new drug approvals from the FDA, one can
argue optimistically that M&A changes the landscape with dif-
ferent market players responsible for different tasks and gener-
ates more intra-dependencies but does not decrease innovation.
8. Five-year view
One can be pretty optimistic that M&A and further consolida-
tions will shape the next years in the pharmaceutical sector.
External and internal conditions factorize and increase M&A
transactions such as volatile market conditions, increase in com-
petition, increasing demand due to an aging population, grow-
ing demand from emerging markets and also increasing patent
expirations. Thereunto, companies have cash as they are selling
of their noncore assets and debt is cheap. Therefore, deal-mak-
ing activities acquiring new drugs or technologies will continue
to trend upward. The future drug pipeline will be guided by
acquisitions and outsourcing as new drug developments are
getting more and more complicated due to rising regulatory
requirements, pricing pressures and are more time intestines.
Key issues
● Changing market due to expiration of blockbusters and
drugs patents
● Difficulties discovering new key innovations creating scien-
tific advantages due to higher macro constraints and differ-
ent market conditions
● Creation of growth through inorganic rather than organic
growth as it allows generating revenues
● Political uncertainties due to elections in the US and Europe
as well as a general overvaluation of companies declined
M&A deal volume in 2016
● The market is waiting for Trump’s key decisions regarding
the US tax reform rate, whether the corporate rate will be
declined from 35% and what conditions regarding repatria-
tion of cash will be defined, as this will shape the M&A
future of US companies
● Currently one sees a Bull market without share prices having
dropped 20% in the S&P 500 sinceMarch 2009 that favourM&A
activity
● Over the next years one can expect an increase in M&A
deals due to favourable market conditions and in order to
reply the demand (i.e. Personalised drugs, advancement in
3D printer etc.
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